Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/22490566http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/22490566http://www.w3.org/2000/01/rdf-schema#comment"

Background

Dihydropyrimidine dehydrogenase (DPD), a key enzyme involved in the catabolism of 5-fluorouracil (5-FU), is the attractive candidate for pharmacogenetic research on efficacies and toxicities of 5-FU. The aim of this study is to explore the association between polymorphisms of dihydropyrimidine dehydrogenase gene (DPYD) and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in the Chinese population.

Methods

Three hundred and sixty-two patients with gastric cancer in the Chinese population were treated with fluorouracil-based adjuvant chemotherapy. The single nucleotide polymorphic genotypes of DPYD were determined by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) using DNA samples isolated from peripheral blood collected before treatment.

Results

The average response rate for chemotherapy was 46.7%. A significantly different distribution of the rs1801159 (c2=8.76, P=0.012) genotypes was observed. Homozygous genotype rs1801159A/A was over-represented in responsive patients. Conversely, carriers of the rs1801159A/G genotype were prevalent in non-responsive patients. In the haplotype association analysis, there was significant difference in global haplotype distribution between the groups (c2=3.96, P=0.0465).

Conclusions

These results suggest that polymorphisms of rs1801159 in DPYD may be used as valuable predictors of the response to fluorouracil-based chemotherapy for gastric cancer patients in the Chinese population. Well-designed, comprehensive, and prospective studies on determining these polymorphisms of DPYD as predictive markers for gastric cancer in response to fluorouracil-based therapies are warranted."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Chen L."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Wang S."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Zhang W.J."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Zhang Z.D."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Wu J.Z."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Yan F."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Jiang Z."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Zhang X.P."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Zhong Y.J."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Lu Z.H."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Tong N."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Feng J.F."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Chen B.A."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Bai Z.B."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Peng M.X."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/author"Xu P.P."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/name"Chin Med J (Engl)"xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/pages"741-746"xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/title"Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population."xsd:string
http://purl.uniprot.org/citations/22490566http://purl.uniprot.org/core/volume"125"xsd:string
http://purl.uniprot.org/citations/22490566http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/22490566
http://purl.uniprot.org/citations/22490566http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/22490566
▶